- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02993575
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients (FANATIC)
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion as Therapy to Patients With an Infection in the Intensive Care Unit (ICU)
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine total and free flucloxacillin concentrations in 30 ICU patients, who will get continuous (n=10) or intermittent infusion (n=20) of flucloxacillin as standard care.
Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing regimen and limited sampling will be taken for individual patients on the continuous dosing regimen on day 2 and 4.
Study Overview
Detailed Description
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared to non-ICU patients. There is a substantial risk that present standard dosing regimens of antibiotics lead to suboptimal outcomes for patients on the ICU. To prevent the risk of inadequate dosing in critically ill patients, it is important to optimize dosing regimens in ICU patients.
With this study the investigators will define pharmacokinetics of flucloxacillin in ICU patients and search for variables influencing pharmacokinetics. By using population modeling the investigators will simulate different dosing regimens, intermittent and continuous, and compare probability of target attainment between continuous and intermittent infusion.
To be able to include 30 patients within the study duration, a multi-centre approach is necessary.
Patients will receive standard care, as stated in the product characteristics or according to local protocols. Minimally invasive blood sampling for pharmacokinetic analysis will be retrieved through a central venous catheter or an arterial line. Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing regimen and limited sampling will be taken for individual patients on the continuous dosing regimen on day 2 and 4.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands
- Radboud University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is admitted to an ICU
- Subject is at least 18 years old on the day of the first dosing
- Is managed with a central venous catheter or arterial line
- Patient is treated with flucloxacillin
Exclusion Criteria:
1. Has previously participated in this trial
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clearance
Time Frame: Day 2 and 4
|
Full pharmacokinetic curves will be taken on Day 2 and Day 4
|
Day 2 and 4
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCN-AKF-16.08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infections
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineWithdrawn
Clinical Trials on Flucloxacillin
-
GlaxoSmithKlineCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminated
-
Universitaire Ziekenhuizen KU LeuvenTerminatedChronic Kidney DiseaseBelgium
-
Murdoch Childrens Research InstituteCompleted
-
The University of QueenslandWithdrawn
-
University of SouthamptonUniversity of Nottingham; Norfolk and Norwich University Hospitals NHS Foundation... and other collaboratorsNot yet recruitingCellulitis of Leg
-
Murdoch Childrens Research InstituteRecruitingOsteomyelitis | Septic Arthritis | Bone Infection | Bone and Joint InfectionNew Zealand, Australia
-
Novartis PharmaceuticalsCompletedInfectionsGermany, Austria, Italy, Russian Federation, Spain
-
University Hospital, Basel, SwitzerlandCompleted
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore